Pneuma Respiratory, which is developing a digital soft mist inhaler, announced that it has completed a Series A financing round that raised $8.3 million.
The company’s Pneumahaler device is a breath activated digital SMI that uses a cartridge system with a microfluidic spray ejector capable of delivering defined droplet sizes.
The company said that its “strategy aims to de-risk its clinical and regulatory pathway and create value by rebranding off-patent therapeutic treatments within its patented Pneumahaler system to improve treatments for patients in the $39+ billion global asthma + COPD market.”
Pneuma Respiratory CEO and founder Eric Hunter said, “We are extremely gratified by the response to our Series A capital raise and look forward to continuing Pneuma’s mission of developing greatly improved therapeutic treatments for patients who suffer from asthma and COPD.”
Read the Pneuma Respiratory press release.
